CSPC Pharmaceutical Group Limited
CHJTF
Other OTC1.05
USD
- -
- -
ISIN
HK1093012172
Return %
Stock
S&P500
1Y
29.63
26.53
3Y
26.51
76.60
5Y
-26.06
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lei Cai
- Full Time Employees
- 21,400
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- No. 226 Huanghe Street Shijiazhuang People's Republic of China 050035
- IPO Date
- Apr 5, 2010
- Website
- cspc.com.hk
- Similar Companies
- Business
- CSPC Pharmaceutical Group Limited (SEHK:1093; OTC:CHJTF) is a leading pharmaceutical company engaged in the research, development, manufacture and sale of finished drugs, bulk drugs and functional foods, with a core focus on innovative drugs across therapeutic areas including nervous system diseases, oncology, anti-infectives, cardiovascular, respiratory, digestion, metabolism and immunology. The company offers an extensive portfolio of finished drugs such as NBP (butylphthalide soft capsules and injections) for acute ischemic stroke; Oulaining (oxiracetam capsules and lyophilised powder for injections) for mild to moderate memory impairment from vascular or senile dementia; Enxi (pramipexole hydrochloride tablets) for Parkinson's disease and restless legs syndrome; Duomeisu (doxorubicin hydrochloride liposome injection) for lymphoma, multiple myeloma, ovarian and breast cancers; Jinyouli (PEG-rhG-CSF injection) to prevent chemotherapy-induced leucopenia; Keaili (albumin-bound paclitaxel injection) for breast cancer; Xuanning (levamlodipine maleate tablets) for hypertension; Shuluoke (meropenem injections) and Weihong/Xinweihong (azithromycin) for bacterial infections; Encun (clopidogrel bisulfate tablets) for atherosclerotic thrombosis; Debixin (omeprazole capsules) for ulcers and reflux esophagitis; Qimaite (tramadol hydrochloride) for pain management; as well as antibiotics, vitamin C, caffeine APIs, glucose products and healthcare services. Bulk drugs encompass antibiotics, vitamin C and caffeine series, while functional foods include caffeine additives, anhydrous glucose and acarbose tablets. CSPC operates primarily in Mainland China with manufacturing facilities concentrated in Shijiazhuang, Hebei Province; it serves domestic and international markets across Asia, Europe, North America and other regions, reaching 114 countries. Founded in 1992 and listed on the Hong Kong Stock Exchange since 1994 (formerly China Pharmaceutical Group Limited until its name change in March 2013), CSPC is headquartered at No. 226 Huanghe Street, Shijiazhuang, 050035, China. The company maintains international R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, emphasizing small molecule targeted drugs, nano-drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and biologics. In recent developments, CSPC secured 16 marketing approvals and 66 clinical trial approvals in 2024, including Omalizumab for Injection (China's first approved biosimilar) in September 2024 and full U.S. FDA approval for Xuanning; it also received three breakthrough therapy designations. The company entered a June 2025 collaboration with AstraZeneca for AI-driven discovery of novel oral drugs targeting immunological diseases (US$110 million upfront plus milestones), building on a prior 2024 AstraZeneca licensing deal for metabolic disorders; in July 2025, it licensed preclinical GLP-1 receptor agonist SYH2086 globally to Madrigal Pharmaceuticals (US$120 million upfront, up to US$2 billion milestones plus royalties). CSPC plans over 50 new product or indication submissions in the next five years and anticipates at least three major out-licensing deals in fiscal 2025, each potentially exceeding US$5 billion in value, while advancing mRNA vaccine and siRNA production capabilities.